Relmada Therapeutics
RLMD56
$0.62arrow_drop_up6.26%$0.03
Penny Stock
RLMD56
$0.62
arrow_drop_up6.26%| Key Stats | |
|---|---|
| Open | $0.59 |
| Prev. Close | $0.61 |
| EPS | -2.86 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $13.72M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 0.57 | 0.66 |
| 52 Week Range | 0.24 | 7.22 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | -2.86 |
| Fundamentals | |
|---|---|
| Gross Profit | - |
| Payout Ratio | - |
| Industry average yield | 2.89% |
| Last Dividend pay date | Sep 30, 2019 |
| Dividend per share | - |
| Dividend yield forecast | - |
Stock Analysis
Technicals
Summarizing what the indicators are suggesting.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Analyst rating
An aggregate view of professional's ratings.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Stock Performance
RLMD-
US Healthcare Sector-
US Market-
check_circle
RLMD / Market
RLMD exceeded the US Market which returned 0.03% over the last twenty four hours.check_circle
RLMD / Healthcare Sector
RLMD exceeded the US Healthcare sector which returned 2.60% over the last twenty four hours.Relmada Therapeutics (RLMD) Statistics
Keep an eye on Relmada Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
How has Relmada Therapeutics (RLMD) stock's performance compared to its sector and the market over the past year?
Over the past year, Relmada Therapeutics (RLMD) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 15.12%, Relmada Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 23.87%, it has fallen short of the market average. This comparison highlights Relmada Therapeutics 's performance relative to both its sector and the overall market over the last year.
help
What is the PE ratio of Relmada Therapeutics (RLMD) stock?
The PE ratio for Relmada Therapeutics (RLMD) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help
What is the EPS of Relmada Therapeutics (RLMD) stock?
The Earnings Per Share (EPS) for Relmada Therapeutics (RLMD), calculated on a diluted basis, is -$2.86. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help
What is the operating margin of Relmada Therapeutics (RLMD) stock?
The operating margin for Relmada Therapeutics (RLMD) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help
What is the EBITDA of Relmada Therapeutics (RLMD) stock?
The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Relmada Therapeutics (RLMD) is $0. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help
How much debt does Relmada Therapeutics (RLMD) have?
Relmada Therapeutics (RLMD) has a total debt of $0. The net debt, which accounts for cash and cash equivalents against the total debt, is -$1.48M.